Can a phone app make immunotherapy easier for kidney cancer patients?
NCT ID NCT05579847
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a smartphone app could help patients with advanced kidney cancer learn about and manage side effects from combination immunotherapy. Twenty patients used the app for six weeks. The goal was to see if patients found the app helpful and if it improved their quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mHealth smartphone application
- What this could lead to
- If successful, this app could help patients better understand and manage treatment side effects, improving their quality of life.
- What could go wrong
- This is a very small, early feasibility study with only 20 participants, so results may not apply broadly. The app is educational only and does not treat the cancer itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States